Evidence map›Paper›PMID 31278356›Full record

ArticleScientific reports2019

Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells.

Hitomi Miyake, Dai Miyazaki, Yumiko Shimizu, Shin-Ichi Sasaki, Takashi Baba, Yoshitsugu Inoue, Kazuki Matsuura

Erratum issuedOpen access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. AcuteInternational journal of ophthalmology · 2024
    Article
  7. Article
  8. Article
  9. Intravitreal triple therapy with vancomycin, ceftazidime, and moxifloxacin for bacterial endophthalmitis: A Twelve-year experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hitomi MiyakeDivision of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Department of Ophthalmology, Nojima Hospital, Tottori, Japan.
Dai MiyazakiDivision of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Department of Ophthalmology, Nojima Hospital, Tottori, Japan. miyazaki-ttr@umin.ac.jp.
Yumiko ShimizuDivision of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Department of Ophthalmology, Nojima Hospital, Tottori, Japan.
Shin-Ichi SasakiDivision of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Department of Ophthalmology, Nojima Hospital, Tottori, Japan.
Takashi BabaDivision of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Department of Ophthalmology, Nojima Hospital, Tottori, Japan.
Yoshitsugu InoueDivision of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Department of Ophthalmology, Nojima Hospital, Tottori, Japan.
Kazuki MatsuuraDivision of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Department of Ophthalmology, Nojima Hospital, Tottori, Japan.
Tottori University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prophylactic intracameral injection of antibiotics is commonly used to prevent endophthalmitis after cataract surgery. However, devastating visual complications have been reported including hemorrhagic occlusive retinal vasculitis (HORV).To determine the toxic and inflammatory effects of moxifloxacin, cefuroxime, and vancomycin on human retinal vascular cells, human retinal vascular endothelial cells (RVEC) and pericytes were exposed to three antibiotics, and the adverse effects were assessed by membrane damage, loss of intrinsic esterase activity, kinetic cell viability, and inflammatory cytokine secretion. Their retinal toxicity was examined by live/dead assays after an intravitreal injection of the three antibiotics into mice eyes. In vascular cells in culture, membrane damage and loss of esterase activity were induced after exposure to the three antibiotics. The toxic effects were most obvious after moxifloxacin (RVEC, ≥125 μg/mL; pericytes, ≥1000 μg/mL) at 24 h. Cefuroxime also reduced esterase activity and the membrane integrity of vascular cells but were less toxic than moxifloxacin. Kinetic cell viability testing showed that 500 μg/mL of moxifloxacin exposure induced significant decrease (29%) in the viability as early as 1 h. When the inflammatory effects of the antibiotics were examined, a significant induction of IL-8 was observed especially by RVECs after exposure to cefuroxime or vancomycin which was exacerbated by L-alanyl-γ-D-glutamyl-meso-diaminopimelic acid (Tri-DAP), a NOD1 ligand. Intravitreal injections in mice showed that cefuroxime and vancomycin caused retinal and vascular toxicity extending to the inner nuclear layers. Collectively, moxifloxacin causes immediate damage to retinal vascular cells in vitro, while cefuroxime and vancomycin induced significant inflammatory effects on vascular endothelial cells and caused retinal toxicity. Surgeons need to be cautious of the toxicity when antibiotics are used prophylactically especially by intravitreal administration.

Indexed as

AnimalsAnti-Bacterial AgentsCefuroximeCells, CulturedCell SurvivalEndothelial CellsEsterasesHumansInterleukin-8Intravitreal InjectionsMiceMoxifloxacinPericytesRetinaVancomycinAnti-Bacterial AgentsCefuroximeEsterasesInterleukin-8MoxifloxacinVancomycin

Identifiers

PMID31278356
PMCPMC6611880
OpenAlexW2954959465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.